Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Labcorp Holdings Hosts 2026 Investor Day

Labcorp Holdings Inc. filed a Form 8-K with the SEC on September 10, 2026, disclosing that the company hosted its 2026 Investor Day and furnished related materials including a press release and presentation covering its growth strategy, innovation roadmap, and long-term financial outlook through …

Anjali Anand | 10 September 2026

Ameresco Names Interim Finance Leaders After CFO Exit

Ameresco, Inc. filed a current report on September 10, 2026, disclosing the designation of two interim finance officers following the previously announced resignation of its Chief Financial Officer.

Anjali Anand | 10 September 2026

Public Storage Prices C$400M Senior Notes Due 2033

Public Storage filed a current report on September 10, 2026, disclosing that it entered into an underwriting agreement on September 9, 2026, for the sale of C$400 million aggregate principal amount of senior notes due 2033, to be issued by its subsidiary PS Canada …

Aditi Sarkar | 10 September 2026

American Eagle Outfitters Files Quarterly Report for August 2026

American Eagle Outfitters, Inc. filed a quarterly report with the U.S. Securities and Exchange Commission on September 10, 2026, covering the 13-week and 26-week periods ended August 1, 2026.

Aditi Sarkar | 10 September 2026

Limitless X Holdings (OTC: LIMX): Rebuilding Sales in a Crowded Wellness Market

Limitless X Holdings is a diversified consumer packaged goods company focused on the nutrition, wellness and beauty sectors. Its model combines product development with direct-response advertising,Digital Marketingservices and direct-to-consumer e-commerce. Recent developments describe an effort to broaden the platform and stabilise the business: the …

Nitish Kishor | 10 September 2026

Aldeyra Therapeutics (NASDAQ: ALDX): Reproxalap's Path After a Third FDA Rejection

Aldeyra Therapeutics is a clinical-stage biotechnology company built around reactive aldehyde species (RASP) modulation, an anti-inflammatory approach. Its lead candidate, reproxalap, is a topical treatment aimed at the signs and symptoms of dry eye disease, a large and competitive ophthalmology market. The pivotal moment …

Nitish Kishor | 10 September 2026

Exicure (NASDAQ: XCUR): From Nucleic-Acid Pioneer to Oncology-Focused Micro-Cap

Exicure was founded on spherical nucleic acid (SNA) technology, developing gene-regulating therapies. That platform is no longer the story. Regulatory data now describe a company that "does not have significant operations" in its former sense, having pivoted after acquiring GPCR Therapeutics USA. The centerpiece …

Nitish Kishor | 10 September 2026

Instil Bio (NASDAQ: TIL): A Cash-Rich Biotech Searching for Its Next Program

Instil Bio originally built its identity around tumor-infiltrating lymphocyte (TIL) cell therapies for cancer. After restructuring, the company shifted toward antibody-based oncologyAssetslicensed from China's ImmuneOnco. That strategy unraveled on January 6, 2026, when Instil's subsidiary, Axion Biosciences, announced it would discontinue clinical development of …

Nitish Kishor | 10 September 2026

Tevogen Inc (NASDAQ: TVGN): Balancing a T-Cell Platform Against Liquidity Strain

Tevogen Bio, which reports as Tevogen Inc., is developing allogeneic, off-the-shelf CD8+ cytotoxic T-cell therapies through a platform it calls ExacTcell. Its lead candidate, TVGN 489, targets high-risk COVID-19 and related indications such as long COVID, and the company has said a Phase 1 …

Nitish Kishor | 10 September 2026

BiomX Inc (NYSE American: PHGE): The BX004 Phage-Therapy Readout Investors Await

BiomX is a clinical-stage company developing natural and engineered phage therapies, viruses that selectively target and kill specific bacteria. Its lead candidate, BX004, is being studied in a Phase 2b trial for chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis, a difficult-to-treat …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…